Dx Dialogues: Metabolic dysfunction-associated steatohepatitis (MASH)
- Dx Dialogues
- Dx Dialogues: Metabolic dysfunction-associated steatohepatitis (MASH)
Medically reviewed in July 2024
In this video series, Dr. Nadege Gunn, MD, DABOM, CPI, FAASLD explores the evolving landscape of diagnosing and managing metabolic dysfunction-associated steatohepatitis (MASH). Dr. Gunn highlights the critical importance of recognizing patients who may otherwise be overlooked and underscores why no patient with MASH should be left behind. She also delves into the latest advancements in treatment, including new agents aimed at halting disease progression and reducing fibrosis, in addition to discussing areas where medication breakthroughs are still needed. Dr. Gunn provides practical insights to help healthcare professionals stay at the forefront of MASH care. These videos were made in collaboration with the Global Liver Institute.
Transcript
Featured Content
Article
MASH: The Silent Epidemic of Metabolic Liver Disease15 million people in the U.S. with MASH face increased risk of cirrhosis, hepatocellular carcinoma and liver transp...
Article
New Frontiers in MASH: Emerging Tools for Liver Assessment and DiagnosisDiagnosing MASH requires a liver biopsy, but less invasive methods are on the horizon.
Article
Expanding Treatment Options for MASH: New Options and Emerging TherapiesTreatment for MASH expands to FDA-approved pharmacotherapy with others in clinical trials.
Article
FDA Approves First-Ever Therapy for MASH with fibrosisFor the first time, patients with non-alcoholic steatohepatitis with scarring have an approved therapy.
